Click here to view a presentation with findings from cohort 2 of a phase 1 clinical trial of GR-MD-02 in fatty liver disease with advanced fibrosis.

Highlights

Galectin Therapeutics, Inc.

NASDAQ: GALT

5.64-8.90
Stock price updates every 30 minutes.

Subscribe

Get the latest updates from Galectin Therapeutics. Please enter your contact information below to sign up: